Page last updated: 2024-12-11

7-hydroxymethotrexate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5385077
CHEBI ID166565
MeSH IDM0058487

Synonyms (21)

Synonym
CHEBI:166565
2-[[4-[(2,4-diamino-7-oxo-8h-pteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
glutamic acid, n-(p-(((2,4-diamino-7-hydroxy-6-pteridinyl)methyl)methylamino)benzoyl)-
nsc380963
n-(4-(((2,4-diamino-7-hydroxy-6-pteridinyl)methyl)(methyl)amino)benzoyl)glutamic acid
5939-37-7
2-[[4-[(2,4-diamino-7-hydroxy-pteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid
nsc380962
7-hydroxymethotrexate
l-glutamic acid,4-diamino-1,7-dihydro-7-oxo-6-pteridinyl)methyl]methylamino]benzoyl]-
glutamic acid,4-diamino-7-hydroxy- 6-pteridinyl)methyl]methylamino]benzoyl]-, l-(+)-
FT-0669736
NCGC00229702-01
2-[[4-[(2,4-diamino-7-keto-8h-pteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid
AKOS030243073
FT-0669737
7-hydroxy methotrexate sodium salt
7-hydroxy mtx
n-[4-[[(2,4-diamino-7,8-dihydro-7-oxo-6-pteridinyl)methyl]methylamino]benzoyl]-l-glutamic acid, trisodium salt
7-hydroxy methoxtrexate
PD060520

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our results may indicate a direct toxic effect of 7-OH-MTX on kidney and liver cells."( Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.
Aarbakke, J; Andersen, A; Bremnes, RM; Eide, TJ; Huseby, NE; Jaeger, R; Smeland, E, 1994
)
0.55
" Monitoring of pharmacokinetics is essential to prevent the development of severe adverse events in adolescents."( Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas, K; Eipel, OT; Erdelyi, DJ; Hegyi, M; Kovacs, GT; Muller, J, 2013
)
0.39
"Drug-induced nephrotoxicity is a frequent adverse event that contributes to acute kidney injury with tubular and/or glomerular lesions."( Interaction of nobiletin with methotrexate ameliorates 7-OH methotrexate-induced nephrotoxicity through endoplasmic reticulum stress-dependent PERK/CHOP signaling pathway.
Chen, Y; Li, C; Liu, B; Liu, G; Liu, L; Liu, R; Liu, Y; Lu, A; Lu, C; Song, Y; Song, Z, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" The 7-OHMTX level increased during each infusion and a Cmax of 19 mumol."( Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Breithaupt, H; Hartmann, R; Henze, G; Hepp, R; Wolfrom, C, 1990
)
0.28
" Pharmacokinetic parameters (metabolic index, drug/metabolite ratio, half-life) of 7-OH-MTX and their relationship to the kinetics of methotrexate were analyzed."( Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
Borsi, JD; Moe, PJ; Romslo, I; Sagen, E, 1990
)
0.28
"05) smaller central compartment of distribution (Vc) and a longer second phase half-life (t1/2(beta)) for 7-OH-MTX."( Pharmacokinetics of 7-hydroxy-methotrexate and methotrexate in the rat.
Aarbakke, J; Jaeger, R; Kjaeve, J; Slørdal, L, 1988
)
0.27
" Methotrexate and 7-hydroxy-methotrexate concentrations were measured by specific radioimmunoassays and the data were analysed simultaneously by an integrated pharmacokinetic model."( Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate.
Bore, P; Bruno, R; Cano, JP; Favre, R; Lena, N, 1987
)
0.27
" Significant interindividual variability was found in time to peak concentration (30-180 min), peak concentration (0."( Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.
Hählen, K; Nooter, K; Schultz, FW; Sonneveld, P, 1986
)
0.27
" Pharmacokinetic studies in humans indicate (i) a higher concentration of 7-OH-MTX than of MTX in plasma after a 24-h infusion and (ii) a time-dependent relationship for MTX and 7-OH-MTX kinetics in plasma and urine which might be explained by the variation of MTX metabolism."( In vitro approach to 7-hydroxymethotrexate interaction on methotrexate metabolism as tool of pharmacokinetic study.
Cano, JP; Catalin, J; Fabre, G; Just, S, 1983
)
0.58
" The disposition kinetics of MTX appeared polyexponential with a small terminal phase having a half-life of 10."( Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration.
Chen, ML; Chiou, WL, 1983
)
0.27
" All animals in the pharmacokinetic study received a single intraperitoneal injection of MTX (10 mg/kg), and serum MTX and 7-hydroxy-methotrexate concentrations were determined using a specific, reversed phase, high-performance liquid chromatography assay."( Effect of protein-calorie malnutrition on methotrexate pharmacokinetics.
Bartlett, D; Charland, SL; Torosian, MH,
)
0.13
" The study demonstrate that the microdialysis technique offers a means to investigate pharmacokinetic drug-drug interactions."( Alterations in methotrexate pharmacokinetics by naproxen in the rat as measured by microdialysis.
Andersen, A; Ekstrøm, PO; Giercksky, KE; Slørdal, L, 1997
)
0.3
"The influence of concomitant administration of piperacillin (PIP) on the pharmacokinetic parameters of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) was studied in rabbits."( Influence of piperacillin on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.
Abou-Auda, HS; Ghilzai, NM; Najjar, TA, 1998
)
0.74
" All AUC(0-infinity), GMR and Cmax GMR 90% CIs fell within the predefined comparability limits of (0."( Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.
Agrawal, NG; Bachmann, KA; Ebel, DL; Gertz, BJ; Holmes, GB; Miller, JL; Porras, AG; Redfern, JS; Sack, MR; Schwartz, JI; Wong, PH, 2001
)
0.31
" In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bid on the pharmacokinetic profile of methotrexate was investigated."( Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M, 2005
)
0.33
"Monitoring the pharmacokinetic parameters of different anticancer drugs is necessary because they might have several side effects."( [Pharmacokinetic analysis of high-dose methotrexate treatments in children with hematologic malignancies].
Csóka, M; Csordás, K; Eipel, O; Hegyi, M; Kovács, G; Pap, E, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" The results, however, demonstrated a change in the bioavailability of the drug (decreasing from 84."( Biliary elimination of low-dose methotrexate in humans.
Furst, DE; Hoffman, J; Koehnke, R; Nuernberg, B; Solsky, M, 1990
)
0.28
" Bioavailability of the drug may be influenced--at least in part--by food intake."( Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis.
Furst, DE, 1985
)
0.27
" and oral administration indicating similar bioavailability after these routes of administration."( The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.
Beck, O; Eksborg, S; Seideman, P; Wennberg, M, 1993
)
0.29
"Subcutaneous methotrexate was well absorbed and distributed to the site of the lesions in patients with inflammatory bowel disease."( Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease.
Egan, LJ; Fauq, AH; Lipsky, JJ; Mays, DC; Sandborn, WJ; Tremaine, WJ, 1999
)
0.3

Dosage Studied

On day 1 of the study, patients with RA receiving stable doses of MTX had blood and urine levels ofMTX and its metabolite 7-hydroxymethotrexate (7-OH-MTX) measured post oral dosing of the drug. Forty-eight hours after MTX dosage the level of 7-Hydroxymetrexate exceeded that of MTx by ten to one.

ExcerptRelevanceReference
"286 (n = 6) mumol/l respectively with the dosage of 400 mg/m2."( [Serum monitoring of methotrexate (MTX) and 7-hydroxymethotrexate concentrations in patients treated with MTX using high-pressure liquid chromatography (HPLC) and comparison of serum MTX levels between HPLC method and fluorescence polarization immunoassay
Matsuhisa, T; Miyoshi, K; Moriwaki, S; Motoi, M; Naruse, R; Okabe, K; Sakamoto, S; Shimokawa, T; Toki, H; Urayama, H, 1991
)
0.54
" Forty-eight hours after MTX dosage the level of 7-hydroxymethotrexate exceeded that of MTX by ten to one."( Methotrexate cytotoxicity: studies on its reversal by folates and nucleosides.
Lankelma, J; Leyva, A; Nederbragt, H; Pinedo, HM, 1981
)
0.52
"The pharmacokinetics of low-dose subcutaneous methotrexate have not been determined throughout the standard weekly dosing interval."( Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease.
Egan, LJ; Fauq, AH; Lipsky, JJ; Mays, DC; Sandborn, WJ; Tremaine, WJ, 1999
)
0.3
" The methotrexate concentration in the rectal mucosa remained within a pharmacologically active range throughout the dosing interval."( Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease.
Egan, LJ; Fauq, AH; Lipsky, JJ; Mays, DC; Sandborn, WJ; Tremaine, WJ, 1999
)
0.3
"On day 1 of the study, patients with RA receiving stable doses of MTX had blood and urine levels of MTX and its metabolite 7-hydroxymethotrexate (7-OH-MTX) measured post oral dosing of the drug."( Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone.
Baggott, JE; Choc, MG; Fox, RI; Morgan, SL; Robbins, BA; Smith, HT, 2003
)
0.73
" Plasma pharmacokinetic studies and cerebral and ventricular microdialysis studies were performed in animals dosed with 200 or 1000 mg/kg MTX by IV bolus."( CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children.
Campagne, O; Davis, A; Owens, TS; Perkins, RS; Stewart, CF, 2023
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
folic acidsA group of heterocyclic compounds based on the pteroic acid skeleton conjugated with one or more L-glutamic acid units.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (164)

TimeframeStudies, This Drug (%)All Drugs %
pre-199082 (50.00)18.7374
1990's37 (22.56)18.2507
2000's25 (15.24)29.6817
2010's16 (9.76)24.3611
2020's4 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.76 (24.57)
Research Supply Index5.19 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (5.95%)5.53%
Reviews4 (2.38%)6.00%
Case Studies4 (2.38%)4.05%
Observational0 (0.00%)0.25%
Other150 (89.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Kinetics of Elimination of Methotrexate and Its Major Metabolite 7-OH-methotrexate for Observant Patients [NCT03852888]62 participants (Actual)Interventional2018-11-14Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]